Taken together, only a small number of preclinical studies have evaluated the impact of long-term treatment with CB2 agonists on tumor growth and cancer cell proliferation (Hanlon et al., 2016; Elbaz et al., 2017). This evidence concerns the gene CNR2 and cancer.